Page 1 of 1

Active Living, Population and Public Health Communicable Disease Control 4th Floor, 300 Carlton St, Winnipeg, MB R3B 3M9 T 204 788-6737 F 204 948-2190

www.manitoba.ca

April 26, 2017

UPDATE: Mumps Outbreak and Testing Processes

Mumps continues to spread throughout Manitoba. As of April 21, 2017, Manitoba Health, Seniors and Active Living (MHSAL) has confirmed 323 cases of mumps in Manitoba since September 1

st 2016. Manitoba typically experiences four to

five cases of mumps per year.

For updated information about mumps, please visit the MHSAL mumps disease webpage: www.gov.mb.ca/health/publichealth/diseases/mumps.html

Updated Reporting and Testing Procedure for Mumps: Testing of suspected clinical cases of mumps are to be conducted by the following:

o Buccal swab for symptomatic cases. The swab should be taken from the area by the parotid duct and placed in viral transport medium. Viral swabs from the parotid duct are best collected within 5 days of disease onset; results of PCR are usually available within 2-5 days. Culture can take 10 days.

o Serology (Mumps IgM and IgG; Red-top tubes) should be done, in addition to buccal swab, where the suspected case is beyond 5 days since symptom onset.

o Urine samples are no longer necessary during this outbreak. o Please provide clinical signs and symptoms and their date of onset on the CPL General Requisition.

The current positivity rate when there is a clinically compatible syndrome is 30-50%.

Manitoba’s Mumps Communicable Disease Protocol outlines the recommended public health management of cases/contacts and health care provider reporting requirements.

(www.gov.mb.ca/health/publichealth/cdc/protocol/mumps.pdf). Infection Prevention and Control: Healthcare facilities should refer to MHSAL’s Routine Practices and Additional Precautions: Preventing the

Transmission of Infection in Health Care located at: www.gov.mb.ca/health/publichealth/cdc/docs/ipc/rpap.pdf.

Health care staff who have 2 documented doses of MMR vaccine are considered to be immune and serology is not required. If serology is inadvertently done in workers who have 2 recorded doses of MMR and results show negative IgG, additional doses of MMR are not required.

For Vaccine Eligibility See: (www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html)

Please share this communication with all colleagues in your department, facility or clinic. For questions, please contact MHSAL at 204-788-6737.

Sincerely,

“Original signed by” “Original signed by”

Richard Baydack, PhD Richard Rusk, DVM, MD, CCFP, MPH

Director Medical Officer of Health

Communicable Disease Control Communicable Disease Control

Sincerely, “Original Signed By” “Original Signed By” Richard Baydack, PhD Carla Ens, PhD Director, Communicable Disease Control Director, Epidemiology & Surveillance Public Health and Primary Health Care Public Health and Primary Health Care Manitoba Health, Healthy Living and Seniors Manitoba Health, Healthy Living and Seniors

Public Health and Primary Health Care Communicable Disease Control 4th Floor, 300 Carlton St, Winnipeg, MB R3B 3M9 T 204 788-6737 F 204 948-2040 www.manitoba.ca

November, 2015 Re: Mumps Reporting and Case Investigation

Reporting of mumps (Mumps virus) is as follows:

Laboratory: All positive laboratory results for Mumps virus are reportable to the Public Health

Surveillance Unit by secure fax (204-948-3044).

Health Care Professional: Probable (clinical) cases of mumps are reportable to the Public Health Surveillance

Unit by telephone (204-788-6736) during regular hours (8:30 a.m. to 4:30 p.m.) AND by secure fax (204-948-3044) on the same day that they are identified. After hours telephone reporting is to the Medical Officer of Health on call at (204-788-8666). The Clinical Notification of Reportable Diseases and Conditions form (http://www.gov.mb.ca/health/publichealth/cdc/protocol/form13.pdf) should be

used.

Cooperation in Public Health investigation is appreciated.

Regional Public Health or First Nations Inuit Health Branch (FNIHB): Once the case has been referred to Regional Public Health or FNIHB, the

Communicable Disease Control Investigation Form (www.gov.mb.ca/health/publichealth/cdc/protocol/form2.pdf) should be completed

and returned to the Public Health Surveillance Unit by secure fax (204-948-3044).

1. Case Definition

1.1Confirmed CaseConsistent clinical illnessa with laboratoryconfirmation of infection in the absence of recentimmunizationb with mumps-containing vaccine.

• Isolation of mumps virus from anappropriate clinical specimen

or

• Detection of mumps virus RNA

or

• Seroconversion or a significant rise inmumps IgG titre between acute andconvalescent sera by any standardserologic assay

or

• Positive serologic test for mumps IgMantibodyc in a person who is eitherepidemiologically linked to a laboratory-confirmed case or has recently travelled toan area of known mumps activity.

OR

Clinical illnessa in a person with an epidemiologicallink to a laboratory-confirmed case (1).

1.2 Probable CaseClinical illnessa in the absence of appropriatelaboratory test results (i.e., no laboratory tests havebeen performed) and in the absence of anepidemiologic link to a laboratory-confirmed casein a person who has recently been to an area ofknown mumps activity (1).

Note: Surveillance for mumps focuses on evidentdisease rather than infection. Therefore, surveillancedefinitions do not take into account asymptomaticor subclinical infections that may be detectable bylaboratory methods.

2. Reporting RequirementsLaboratory:

• All positive laboratory results should befaxed (204-948-3044 secure fax) toManitoba Health, Public HealthSurveillance Unit.

• Operators of Manitoba clinical laboratoriesare required to submit to CadhamProvincial Laboratory (CPL) the residualserum, plasma or respiratory specimens orrespiratory viral isolate sub-cultures fromindividuals who tested positive for mumpsvirus within seven days of report.

Health Care Professional:

• The Communicable Disease ControlInvestigation Form (available at:www.gov.mb.ca/health/publichealth/cdc/protocol/form2.pdf)should be faxed (204-948-3044 securefax) to Manitoba Health, Public HealthSurveillance Unit when a healthprofessional becomes aware that a personmeets or has recently met the probable orconfirmed case definition for mumps.

a Characterized by acute onset of unilateral or bilateraltender, self-limited swelling of the parotid or othersalivary gland, lasting > 2 days, and without otherapparent cause. A laboratory-confirmed case may notexhibit clinical illness, as up to 30% of cases areasymptomatic (1).

b The most frequent reaction to Measles-Mumps-Rubella(MMR) immunization is malaise and fever (with orwithout rash) occurring 7-12 days after immunization.Parotitis has occasionally occurred after immunization.However, this should be determined for each case asthese reactions and timeframes can vary (1) (refer tocurrent Canadian Immunization Guide).

c IgM serology may be a false positive. If the clinicalpresentation is inconsistent with a diagnosis of mumpsor in the absence of recent travel/exposure history, IgMresults must be confirmed by another listedconfirmatory method (1).

Communicable Disease Management Protocol

July 20101

Communicable Disease Control Branch

Communicable Disease Management Protocol – Mumps

Mumps

3. Clinical PresentationProdromal symptoms are usually non-specific andmay include low-grade fever, anorexia, malaise andheadache (2). The most prominent manifestationsof this disease are swelling and tenderness of thesalivary glands; one or both parotid glands areaffected in most cases (2). Generalized nonspecificsymptoms or primarily respiratory symptoms occurin about half of infected persons (3). Symptomsusually resolve three to 10 days after onset of illness(2). Subclinical infection is common (3).

Central nervous system (CNS) involvement (i. e.,aseptic meningitis) is the most common extrasalivarygland manifestation of mumps (2, 4). Orchitis is acommon complication in men after puberty, butseldom results in sterility (5). Other rarecomplications include arthritis, thyroiditis, mastitis,glomerulonephritis, myocarditis, endocardialfibroelastosis, thrombocytopenia, cerebellar ataxia,transverse myelitis, ascending polyradiculitis,pancreatitis, oophoritis and deafness (5).

In the absence of immunization, mumps usuallyoccurs in childhood (5). Infection tends to be moresevere in adults (5).There is no firm evidence thatmumps during pregnancy causes congenitalabnormalities (2, 5). Mumps infection during thefirst trimester of pregnancy is associated with anincreased rate of spontaneous abortion (5).

4. EtiologyMumps virus is a member of the Paramyxoviridaefamily (2), genus Rubulavirus (6). Multiplegenotypes (strains) of the mumps virus exist (7),but there is only one serotype (2).

5. Epidemiology

5.1 Reservoir and Source

Humans are the only known natural host (2). Acarrier state is not known to exist in humans (2).

5.2 Transmission

By droplet spread and by direct contact with thesaliva of an infected person (e.g., from coughing,

sneezing, sharing drinks or kissing) (6, 7). Immunizedindividuals do not transmit mumps vaccine virus (5).Importation from countries with low vaccinecoverage rates presents an ongoing risk to under-vaccinated individuals and communities (8).

5.3 Occurrence

General: Endemic worldwide (2). In temperateclimates, winter and spring are peak seasons (6).The incidence of mumps remains high incountries without childhood mumps vaccination,particularly in children aged five to nine years (6).

Canada: From 2000-2006, an average of 79 caseswere reported annually, ranging from 28 in 2003,to 202 cases in 2002 (9). The age distribution ofmumps in Canada has changed following theintroduction of universal childhoodimmunization—the proportion of cases aged 20years and older increased from 14% in 1988-1990, to 64% in 2003-2005 (9). Conversely, theproportion of cases aged 1-9 years fell from 49%to 17% during the same period (9).

Manitoba: Three cases were reported in 2006,eight cases in 2007 and two cases in 2008. In2007, cases occurred over a wide agedistribution, from under one year of age to 40-49 years. In 2009, an outbreak occurred in acorrectional facility, resulting in five cases.

5.4 Incubation Period

The average incubation period for mumps is 16-18days with a range of 12-25 days (5, 6).

5.5 Host Susceptibility and Resistance

Mumps is uncommon in infants younger than oneyear of age due to transplacental maternal antibody(2). Mumps infection confers lifelong immunity(2). The duration of vaccine-induced immunity isunknown (9). Mumps outbreaks have beenreported in highly vaccinated populations (3, 10-13). It is not known whether primary vaccinefailure or waning immunity is the reason formumps in vaccinated individuals (9). Individualsare presumed to be immune to mumps if they havedocumented evidence of vaccination (2 doses ofmumps-containing vaccine at least 28 days apart)

Communicable Disease Management Protocol

July 20102

Communicable Disease Management Protocol – Mumps

on or after their first birthday, laboratory evidenceof immunity, documented history of laboratory-confirmed mumps infection, or if they were bornbefore 1970d (3, 9). Individuals born between 1970and 1990 (to a lesser extent through 1994) shouldbe considered susceptible in the absence of evidenceof immunity as they are too young to have acquirednatural immunity and too old to have beenincluded in the routine two-dose measles-mumps-rubella (MMR) immunization programs (7).

In 1996 a second dose of MMR vaccine forprotection against measles was introduced inManitoba, given at school entry to children bornduring or after 1991. A school-based catch-upprogram for children born during 1985 to 1990was also introduced in Manitoba in 1996 using themeasles-rubella (MR) vaccine (mumps vaccine wasnot included).

5.6 Period of Communicability

Virus is isolated in saliva from seven days before theonset of parotitis to nine days afterwards and inurine from six days before onset of parotitis to 15days after. Maximum infectiousness occurs fromtwo days before onset of illness to four daysafterwards. Persons with inapparent illness cantransmit infection (6). For this document, theperiod of communicability is considered to befrom seven days before to five days after onset ofparotitis (5-7, 14).

6. Laboratory DiagnosisInformation which must be provided on thelaboratory requisition by the health care provider:

• Brief clinical history (signs andsymptoms)

• Date of onset of symptoms

• Date of collection of specimen

• Type of specimen

• Any epidemiological link to a knownmumps case

Testing for mumps-specific IgM-class antibody hassub-optimal sensitivity for the diagnosis of acute

cases in partially immunized populations (7). Ofthe tests which are currently available for viraldetection, reverse transcriptase polymerase chainreaction (RT-PCR) is preferred (7). Both swab forviral detection and serology specimen should besubmitted; however, depending on the number andtiming of samples received by the laboratory,prioritization of testing may occur. Therefore, notall specimens may be processed.

Viral Detection:

Cadham Provincial Laboratory (CPL) virologysection (204-945-6123, after hours204-945-6655) should be consulted prior tosending specimens for virus detection. Allspecimens for mumps virus detection by cultureor mumps virus RNA (RT-PCR) should betransported with a cold pack (to maintain atemperature of approximately 4°C) to CPL assoon as possible (within 24-48 hours ofcollection to preserve optimal specimenintegrity).

A swabe should be taken from the buccal mucosa inthe area by the parotid duct (second upper molar area,i.e., space between the cheek and back teeth adjacentto the swollen gland) and placed in viral transportmedium. For unilateral parotitis, the swab should becollected from the affected side. Optimal time forcollection is within five days of symptom onset.Results for detection of mumps virus RNA (RT-PCR)are usually available within three to five days. Virusisolation by culture may take up to 10 days.

Serology:

Acute and convalescent serum specimens (5-10 cceach) for detection of mumps antibodies should besent approximately 10 days apart. Both mumpsIgM and mumps IgG testing should be specificallyrequested.

d The age at which natural immunity to mumps can beassumed to have been acquired is not known withcertainty. Some individuals born before 1970 may stillbe susceptible to mumps (7).

e Acceptable swabs include either flocked or non-flockedDacron, nylon or rayon tipped swabs. Calcium alginateswabs are not acceptable, nor are swabs with wooden oraluminum shafts.

Communicable Disease Management Protocol

July 20103

Communicable Disease Management Protocol – Mumps

7. Key Information for Public HealthResponse• Immunization history including date(s)

and type of vaccine if known.

• Recent exposure/travel history of cases(e.g., 12-25 days before onset ofparotitis).

• Identification and appropriate follow-upof susceptible contacts.

8. Control

8.1 Management of CasesReported cases are referred by Manitoba Health tothe Regional Health Authority (RHA) of patientresidence or First Nations Inuit Health (ifapplicable) for follow-up. Probable cases should bemanaged as confirmed cases until laboratoryevidence becomes available (7).

• Droplet Precautions in addition toRoutine Practices should be followedwhen individuals with probable mumpspresent to a health care setting. Refer toInfection Control Guidelines: RoutinePractices and Additional Precautions forPreventing the Transmission of Infection inHealth Care. Canada CommunicableDisease Report CCDR, 1999; 25S4: 1-142.

• All cases should be offered supportive careand be encouraged to practice good handhygiene, avoid sharing drinking glasses orutensils, and cover coughs and sneezeswith a tissue or forearm (7).

• All cases should be advised to stay home(self-isolate) from school, post-secondaryeducational institutions, child carefacilities, workplaces and other groupsettings for five days after symptom onset(7). Cases should be advised to present tohealth care facilities only for urgentmedical issues during this time.

• Cases who are health care workers(HCWs) should be advised toimmediately notify Occupational Healthand/or Infection Prevention and Controlfor the facility/regional program in whichthey work and in consultation with themdetermine fitness to return to work (7). Ahealth care worker (HCW) includesindividuals who have the potential toacquire infection from or transmitinfection to others (e.g., patients, staffmembers, visitors) during the course oftheir work and includes nurses, physicians,other hospital workers, students,volunteers, home-care workers, emergencyresponders, and support staff (7).

Public Health Measures:

• Exclusion of Cases: It is recommendedthat cases be excluded from school,workplace, community settings andhealth care facilities (except for urgentmedical issues) until five days after onsetof parotitis (6, 7, 14-16). Care giversshould be advised to keep excludedchildren away from other children andsusceptible adults during the exclusionperiod (7).

• Hospitalized Patients: Cases in healthcare facilities should be managed withDroplet Precautions in addition toRoutine Practices until five days aftersymptom onset (7).

8.2 Management of ContactsThe Regional Health Authority of case residence orFirst Nations Inuit Health (FNIH) (if applicable)will contact reported cases to establish a list ofexposed persons and identify susceptible contacts.

Definitions:

Contact: An individual meeting one or more of thefollowing criteria within the period ofcommunicability of the mumps virus (i.e.,approximately seven days before to five days afteronset of parotitis):

Communicable Disease Management Protocol

July 20104

Communicable Disease Management Protocol – Mumps

• living in the same household as a case;

• sharing sleeping arrangements with a case,including shared rooms (e.g.,dormitories);

• having direct contact with the oral/nasalsecretions of a case (e.g., face-to-facecontact, sharing cigarettes/drinkingglasses/food/cosmetics such as lip gloss,kissing on the mouth);

• children and staff in child care and schoolfacilities (if applicable based on theepidemiology of the outbreak);

• in the health care setting (includes acutecare and long-term care facilities, as wellas home care): if unprotected face-to-faceinteraction within one metre of aninfectious mumps case occurred (7).

Susceptible Contact: For HCWs, refer to“Contacts who are Health Care Workers (HCWs)”below. A contact (defined above) born during orafter 1970f and not meeting any of the followingcriteria:

• Documented evidence of vaccination withtwo doses of mumps-containing vaccineadministered at least 28 days apart on orafter their first birthday;

• Laboratory evidence of immunityg;

• Documented history of laboratoryconfirmed mumps infection (9).

8.21 Recommendations for SusceptibleContacts

• Susceptible contacts should be offeredimmunization with measles-mumps-rubella (MMR) vaccine unlesscontraindicated (7). Although mumpsimmunization after exposure to mumpsmay not prevent the disease, it does notconfer greater risk than administering thevaccine at other times (3). Should theexposure not result in an infection, thevaccine should confer protection againstfuture exposures (3). A second post-exposure dose of MMR vaccine given at

least 28 days after the first post-exposuredose is indicated only for susceptiblecontacts who received no doses ofmumps-containing vaccine prior to theexposure (i.e., no pre-exposure doses).Susceptible contacts who received onedose of mumps-containing vaccine priorto the exposure (i.e., pre-exposure dose)do not require a second post-exposuredose of MMR vaccine. Routine post-immunization serology is not indicated(3). Passive immunization withimmunoglobulin (Ig) is not effective inpreventing mumps (7).

• Susceptible contacts should be educatedabout the early signs and symptoms ofmumps and advised to present to a healthcare provider should symptoms occur (7).It is recommended that symptomaticcontacts call first before presenting to ahealth care facility or provider to reducethe possibility of transmission (7).

• Quarantine of mumps-susceptiblecontacts is not recommended (7).

• All susceptible contacts should beencouraged to practice good handhygiene, avoid sharing drinking glasses orutensils, and cover coughs and sneezeswith a tissue or forearm.

• Susceptible contacts that are in a healthcare facility should be managed usingDroplet Precautions in addition toRoutine Practices from day 10 after firstexposure until day 26 after last exposureinclusive to cover the incubation periodand prevent potential transmission ofdisease (7).

f The age at which natural immunity to mumps can beassumed to have been acquired is not known withcertainty. Some individuals born before 1970 may stillbe susceptible to mumps (7).

g Routine pre-employment laboratory screening formumps immunity is not recommended.

Communicable Disease Management Protocol

July 20105

Communicable Disease Management Protocol – Mumps

8.22 Recommendations for Contacts who areHealth Care Workers (HCWs)

Refer to contact definition above. Therecommendations below apply to all exposedHCWsh, regardless of the HCW’s birth date (i.e., ifborn before, during or after 1970) (7).

Advise HCWs to immediately notify OccupationalHealth and/or Infection Prevention and Control forthe facility/regional program in which they workwho will:

• Provide information about mumps diseaseand its symptoms;

• Assess immunity to mumps if notpreviously assessed and provideimmunization when necessary unlesscontraindicated (e.g., pregnant,immunocompromised):

– If prior documented two doses ofmumps-containing vaccine, can returnto work immediately;

– If documented laboratory-confirmedmumps infection, can return to workimmediately;

– If documented one dose of mumps-containing vaccine, provide a dose ofMMR vaccine and return to workimmediately; or

– If undocumented immunizationhistory and no previous laboratory-confirmed mumps infection:

• Draw blood for mumps IgGserology;

• Provide a dose of MMR vaccine(after blood specimen taken);

• Begin HCW exclusion from day 10after first exposure until serologyresults are received;

• When serology results are received:

– If mumps IgG positive,consider immune and allow

return to work but consider asecond MMR vaccine dose foradequate measles protection.

– If mumps IgG negative, thenconsider susceptible, provide asecond dose of MMR vaccine28 days after the first andcontinue to exclude from workuntil day 26 after last exposureinclusive to prevent potentialtransmission of disease.

8.3Management of OutbreaksDefinition of Outbreak: Confirmed cases in excessof what is expected in the jurisdiction over a givenperiod of time (7).

Refer to sections 8.1 and 8.2 above formanagement of cases and contacts.

Additional Recommendations:

• Public notification should occur: the levelof notification will be at the discretion ofregional Public Health and/or the Officeof Disaster Management.

• Mumps-containing vaccine should begiven to susceptible at-risk populationsduring outbreaks, unless contraindicated.At-risk populations will need to bedefined by the specifics of the outbreak.No more than two doses of MMRvaccine are currently recommended (9).

• Parents/guardians of students whocontinue to be exempted from mumpsimmunization because of medical,religious or other reasons should beadvised about the signs, symptoms andpotential complications of mumpsinfection and the need for exclusion ofchildren who develop symptoms.

h As the recommendations in this protocol reflect recentupdated Public Health Agency of Canada guidelines,implementation in regions/health care facilities willoccur over time.

Communicable Disease Management Protocol

July 20106

Communicable Disease Management Protocol – Mumps

Refer also to the Public Health Agency of Canadadocument Guidelines for the Prevention and Controlof Mumps Outbreaks in Canada.

8.4 Preventive Measures• Prompt identification and management of

cases and contacts as described above insections 8.1 and 8.2.

• Routine Practices in health care settings.

• In non-health care settings:

– Cleaning frequently touchedenvironmental surfaces with a householdcleaner on a regularly scheduled basis

– Practicing cough etiquette and handhygiene on a regular basis

– Cleaning reusable items contaminatedwith respiratory secretions

• Immunization:

Note: Not all recommended vaccinesand immune globulins are provided byManitoba Health (e.g., second MMRdose for adults who are students atpost-secondary institutions). Refer toeligibility criteria for high riskindividuals available at:www.manitoba.ca/health/publichealth/cdc/vaccineeligibility.html

– Children: Routine two-doseimmunization of all children, unlesscontraindicated (3). Infants shouldreceive a first dose combined withmeasles and rubella vaccines (MMR)on or shortly after their first birthday;the second dose should be given atleast 28 days after the first dose andafter 15 months of age, but beforeschool entry (3).

– Adults (non-HCWs):Recommendations for HCWs arecovered in the section below.

• Immunization of non-immuneadults (i.e., born during or after1970), unless contraindicated (9).

• A second dose of MMR should beoffered only to adults born duringor after 1970 who are at greater riskof exposure specifically (9);

– Military recruits

– Students at post-secondaryinstitutions

• One dose of MMR vaccine couldbe considered among high-riskadults (e.g., military personnel)born before 1970 who do not havelaboratory evidence of immunity ora history of laboratory-confirmedmumps disease (9).

Please refer to the supplemental statements from theNational Advisory Committee on Immunization(NACI) for more information. Refer to the currentCanadian Immunization Guide as well as themanufacturer’s package insert instructions for clinicaluse information on mumps-containing vaccine.

For Health Care Workers (HCWs):

Note 1: Mumps outbreak managementrecommendations below reflect recent updatedPublic Health Agency of Canada guidelines (7).

• Pre-placement of HCWs: OccupationalHealth or equivalent should documentHCW immune status at the pre-placementexamination and provide MMR vaccine ifnot immune. An HCW is consideredimmune to mumps if there is:

– Documented evidence of vaccinationwith two doses of mumps-containingvaccine administered at least 28 daysapart on or after their first birthday.

– Laboratory evidence of immunityi.

– Documented history of laboratoryconfirmed mumps infection.

i Routine pre-employment laboratory screening formumps immunity is not recommended.

Communicable Disease Management Protocol

July 20107

Communicable Disease Management Protocol – Mumps

• Existing HCWs: Occupational Health orequivalent should provide MMR vaccineto all HCWs who are not immune tomumps and who do not have a validcontraindication to measles, mumps andrubella (MMR) vaccine.

9. Additional Resources• Manitoba Immunization Schedules –

available at:www.manitoba.ca/health/publichealth/cdc/schedule.html

• Canadian Immunization Guide

References1. Public Health Agency of Canada. Case

Definitions for Communicable Diseases underNational Surveillance. Canada CommunicableDisease Report CCDR 2009; 35S2: 1-123.

2. Litman N and Baum SG. Mumps Virus. In:Mandell GL, Benell JE, Dolin R eds. Principlesand Practice of Infectious Diseases 6th ed.Elsevier, Philadelphia, 2007; 2002-2007.

3. National Advisory Committee on Immunization.Canadian Immunization Guide 7th ed. PublicHealth Agency of Canada, 2006; 251-255.

4. Centers for Disease Control and Prevention.Chapter – Mumps. Epidemiology andPrevention of Vaccine-Preventable Diseases, ThePink Book: Updated 11th Edition 2009; 189-198.

5. American Academy of Pediatrics. Mumps. In:Pickering LK ed. Redbook 2009 Report of theCommittee on Infectious Diseases 28th ed. ElkGrove Village, IL: American Academy ofPediatrics, 2009; 468-472.

6. Heymann David L. Mumps. In: Control ofCommunicable Diseases Manual 19th ed,American Public Health Association,Washington, 2008; 431-435.

7. Public Health Agency of Canada. Guidelinesfor the Prevention and Control of MumpsOutbreaks in Canada. Canada CommunicableDisease Report CCDR, 2010; 36S1: 1-46.

8. The Public Health Agency of Canada.Canadian National Report on Immunization,2006. Canada Communicable Disease ReportCCDR 2006; 32S3: 1-44.

9. National Advisory Committee onImmunization (NACI). Statement on MumpsVaccine. Canada Communicable Disease ReportCCDR 2007; 33: ACS-8.

10. Watson-Creed G, Saunders A, Scott J et al.Two successive outbreaks of mumps in NovaScotia among vaccinated adolescents and youngadults. CMAJ 2006; 175(5): 483-488.

11. Barsky AE, Glasser JW and LeBaron CW.Mumps resurgences in the United States: Ahistorical perspective on unexpected elements.Vaccine 2009; 27: 6186-95.

12. Dayan GH and Rubin S. Mumps Outbreaks inVaccinated Populations: Are Available MumpsVaccines Effective Enough to PreventOutbreaks? Clinical Infectious Diseases 2008;47: 1458-67.

13. Marin M, Quinlisk P, Shimabukuro T et al.Mumps vaccination coverage and vaccineeffectiveness in a large outbreak among collegestudents – Iowa, 2006. Vaccine 2008; 26:3601-7.

14. Centers for Disease Control and Prevention.Updated Recommendations for Isolation ofPersons with Mumps. Morb Mortal Wkly RepMMWR 2009; 57(40): 1103-1105.

15. Bitsko RH, Cortese MM, Dayan GH et al.Detection of RNA of Mumps Virus during anOutbreak in a Population with a High Level ofMeasles, Mumps, and Rubella VaccineCoverage. Journal of Clinical Microbiology2008; 46(3): 1101-1103.

16. Okafuji Takao, Yoshida Naoko, Fujino Motokoet al. Rapid Diagnostic Method for Detectionof Mumps Virus Genome by Loop-MediatedIsothermal Amplification. Journal of ClinicalMicrobiology 2005; 43(4): 1625-1631.

Communicable Disease Management Protocol

July 20108

Communicable Disease Management Protocol – Mumps